Role of expression of cell cycle inhibitor p27 and MIB-1 in predicting lymph node metastasis in male breast carcinoma

Breast Journal

Volumn 8, Issue 2, 2002, Pages 101-107

  Anderson, Joseph ^a   Reddy, Vijaya B ^a   Green, Linda ^b   Bitterman, Pincas ^a   Borok, Raphael ^a   Maggi Galluzzi, Christina ^a   Montironi, Rodolfo ^c   Wick, Mark ^d   Gould, Victor E ^a   Gattuso, Paolo ^a,e  

^a RUSH MEDICAL COLLEGE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Lymph nodes metastases; Male breast cancer; MIB 1; P27

Indexed keywords

MONOCLONAL ANTIBODY KI 67; PROTEIN P27;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER SURGERY; CELL CYCLE; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; LYMPH NODE METASTASIS; MALE; MASTECTOMY; PROTEIN EXPRESSION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NUCLEAR; BREAST NEOPLASMS, MALE; CELL CYCLE; CHI-SQUARE DISTRIBUTION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; PROLIFERATING CELL NUCLEAR ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0036123359     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.2002.08206.x     Document Type: Article

References (70)

1. Male breast cancer
2. Deregulated expression of p27 in human breast cancers
3. Prognostic impact of cyclin dependent kinase inhibitor p27 in node-positive breast cancer
4. Loss or altered subcellular localization of cyclin dependent kinase inhibitor p27 is associated with poor prognosis in Barrett's associated adenocarcinoma
5. The cell cycle in breast cancer
6. MIB-1 labeling index is an independent prognostic marker in primary breast cancer
7. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: Its relationship with vimentin and p53 protein
8. Assessment of the new proliferative marker MIB-1 in breast carcinoma using image analysis: Associations with other prognostic factors and survival
9. The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer
10. Molecular markers in male breast cancer
11. Immunohistochemical techniques for immunofluorescence, immunoenzyme and immunoelectron microscopy
12. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
13. K1p1 protein: Prognostic implications in primary breast cancer
14. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1,b) invasive breast carcinomas
15. K1p1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients
16. Histologic types and hormone receptors in breast cancer in men
17. Prognosis of breast cancer in males: An analysis of 170 cases
18. The prognosis of breast cancer in males
19. A 50 year experience of male breast cancer: Is this outcome changing?
20. Male breast carcinoma: A review of 301 cases from the Christie hospital and holt radium institute, Manchester
21. Metastasis of prostatic carcinoma of the breast
22. Carcinoma of the breast in transsexual individuals after surgical and hormonal interference with the primary and secondary sex characteristics
23. Breast cancer in a male to female transsexual: A case report
24. Occupational risks for male breast cancer in Sweden
25. Risk factors for male breast cancer: A Franco Swiss case-control study
26. Carcinoma of the male breast in Zambia
27. Some epidemiologic features of breast cancer of males
28. Endocrine epidemiology of male breast cancer
29. Hormones in male breast cancer
30. Familial breast cancer in males: Case report and review of the literature
31. Familial male breasts carcinoma
32. Gynecomastia
33. Prognostic significance of DNA ploidy in male breast carcinoma
34. K1p1 protein: Prognostic implications in primary breast cancer
35. The cell cycle inhibitor p27 is an independent: Prognostic marker in small (T1a,b) invasive breast carcinomas
36. K1p1 expression and interaction with other cell cycle-associated proteins in mammary carcinoma
37. K1p1 and apoptosis in human breast cancer
38. K1p1 and cyclin E, alone and in combination, correlate with survival in young breast patients
39. p27 Expression as a prognostic factor of breast cancer in Taiwan
40. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer
41. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor, p27, in aggressive colorectal carcinomas
42. Proliferative index in breast carcinoma determined in situ by Ki-67 immunostaining and its relationship to clinical and pathological variables
43. A simple index to predict prognosis independent of axillary node information in breast cancer
44. Marker panel predictive of lymph node metastasis in young patients with breast carcinoma
45. Proliferation markers in breast carcinoma: Mitotic figure count, S-Phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1
46. Prognostic value of vascular density and cell proliferation in breast cancer patients
47. Proliferative activity is a significant prognostic factor in male breast carcinoma
48. Mutations of the p53 gene in male breast cancer
49. The c-erbB-2 protein in oncogenesis: Molecular structure to molecular epidemiology
50. The c-erb-2 protooncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-a review
51. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer
52. DNA ploidy, proliferation, and neu-oncogene protein overexpression in breast carcinoma
53. Male breast carcinoma: An evaluation of prognostic factors contributing to a poorer outcome
54. Comparison of prognostic markers detected by immunohistochemistry in male, female breast carcinomas
55. p53 and HER-2 neu are rarely imunohistochemically detectable in male breast cancer
56. Lack of c-erbB-2 oncoprotein expression in male breast carcinoma
57. C-erb-B-2 expression in male breast carcinoma
58. Expression of the oerbB2 proto-oncogene in male breast carcinoma: Lack of prognostic significance
59. Prognostic value of intratumoral microvessel density, a measure a tumor angiogenesis, in node negative breast carcinoma-results of a multiparametric study
60. Tumor angiogenesis in node negative breast carcinomas-relationship with epidermal growth factor receptor, estrogen receptor, and survival
61. Angiogenesis, assessed by platelet endothelial adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer
62. Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: A multiparametric and immunohistochemical analysis
63. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma
64. Prognostic significance of microvessel density in lymph node negative breast carcinoma
65. Is the relationship between angiogenesis and metastasis in breast cancer real?
66. Tumor angiogenesis: A new significant and independent prognostic indicator in early stage breast carcinoma
67. Prognostic value of vascular density and cell proliferation in breast cancer patients
68. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH 39
69. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma
70. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment